NICE recommends tocilizumab as a possible treatment for some children and young people with systemic juvenile idiopathic arthritis.
NICE does not recommend tocilizumab for children and young people whose disease is improving with methotrexate treatment, or who have not yet been treated with methotrexate.
Children and young people should be able to have tocilizumab if they have tried all of the following drugs but they have not worked: NSAIDs (non-steroidal anti-inflammatory drugs), systemic corticosteroids and methotrexate.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended tocilizumab because it is clinically effective and it is a cost effective use of NHS resources compared with other treatments currently used in clinical practice.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.